Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation

ERK5, encoded by MAPK7, has been proposed to play a role in cell proliferation, thus attracting interest as a cancer therapeutic target. While oncogenic RAS or BRAF cause sustained activation of the MEK1/2-ERK1/2 pathway, ERK5 is directly activated by MEK5. It has been proposed that RAS and RAF prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Lochhead, Pamela A., Clark, Jonathan, Wang, Lan-Zhen, Gilmour, Lesley, Squires, Matthew, Gilley, Rebecca, Foxton, Caroline, Newell, David R., Wedge, Stephen R., Cook, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Extra View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056618/
https://www.ncbi.nlm.nih.gov/pubmed/26959608
http://dx.doi.org/10.1080/15384101.2015.1120915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056618/
https://www.ncbi.nlm.nih.gov/pubmed/26959608
http://dx.doi.org/10.1080/15384101.2015.1120915

Ejemplares similares